231 results on '"Spelman, Lynda"'
Search Results
2. The 15-year itch: A case of chronic atopic dermatitis unresponsive to topical corticosteroids
3. Deucravacitinib in Plaque Psoriasis: 3-year Safety and Efficacy Results from the Phase 3 POETYK PSO-1 and PSO-2 Trials
4. 494 - Efficacy and safety of lebrikizumab is maintained to two years in patients with moderate-to-severe atopic dermatitis
5. Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials
6. A first-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and safety in skin cancer patients
7. Dupilumab Maintains Long-Term Disease Control in Adults with Moderate-to-Severe Atopic Dermatitis as Measured by Well-Controlled Weeks: Results From the LIBERTY AD CHRONOS Clinical Trial
8. Efficacy and safety analysis: 24‐month outcomes from a prospective cohort of 106 fields treated with widefield radiation therapy for extensive skin field cancerization, with or without keratinocyte cancers.
9. Deucravacitinib in Plaque Psoriasis: 3-Year Safety and Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials
10. Efficacy and Safety of Lebrikizumab Is Maintained to Two Years in Patients With Moderate-to-Severe Atopic Dermatitis
11. Deucravacitinib in Plaque Psoriasis: Maintenance of Response Over 3 Years in the Phase 3 POETYK PSO-1 and PSO-2 Trials
12. Rademikibart (CBP‐201), a next‐generation monoclonal antibody targeting human IL‐4Rα: Two phase I randomized trials, in healthy individuals and patients with atopic dermatitis
13. ISID0459 - Demographics, comorbidities and disease severity before dupilumab treatment initiation in Asian patients with atopic dermatitis
14. Patterns and cost of care according to keratinocyte cancer risk stratification in a volunteer population screening clinic: Real‐world data from the TRoPICS study
15. Safety and longevity of biologic treatment in the setting of moderate to severe psoriasis – enhancing the body of evidence
16. Deucravacitinib long-term efficacy with continuous treatment in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program
17. Deucravacitinib in plaque psoriasis: 2-year laboratory results from the phase 3 POETYK PSO program
18. Deucravacitinib in plaque psoriasis: 2-year laboratory results from the phase 3 POETYK PSO program
19. Deucravacitinib long-term efficacy and safety in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program
20. Dupilumab‐associated ocular surface disease: An interdisciplinary decision framework for prescribers in the Australian setting
21. 33259 Improvements in anxiety and depression among patients with moderate to severe plaque psoriasis treated with certolizumab pegol: Three-year results from 2 phase 3 trials (CIMPASI-1 and CIMPASI-2)
22. 34658 Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate to severe plaque psoriasis who had inadequate responses to apremilast at week 24 in the phase 3 POETYK PSO-1 and PSO-2 trials
23. Secukinumab treatment showed improved quality of life in patients with chronic plaque psoriasis in Australia: Results from the HOPE study
24. Daylight-Mediated Photodynamic Therapy for Actinic Keratosis: Best Practice Guidelines
25. Method of Assessing Skin Cancerization and KeratosesTM (MASCK™): development and photographic validation in multiple anatomical sites of a novel assessment tool intended for clinical evaluation of patients with extensive skin field cancerization
26. Successful management of Australian patients with extensive skin field cancerization (ESFC) with widefield volumetric arc radiation therapy (VMAT): Report with 12-month follow-up.
27. Radiotherapy, Utilizing Volumetric Modulated Arc Therapy, for Extensive Skin Field Cancerization: A Retrospective Case Series Assessing Efficacy, Safety, and Cosmetic Outcomes at 12 Months After Treatment
28. Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials
29. Assessing long-term maintenance of efficacy with tralokinumab monotherapy in patients with moderate-to-severe atopic dermatitis: combined results from two phase 3, randomized, double-blind, placebo-controlled trials (ECZTRA 1 and 2)
30. Treatment of face and scalp solar (actinic) keratosis with daylight-mediated photodynamic therapy is possible throughout the year in Australia: Evidence from a clinical and meteorological study
31. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
32. 27275 Atopic dermatitis treated safely with dupilumab during pregnancy: A case report and review of the literature
33. 28171 Assessing long-term maintenance of efficacy with tralokinumab monotherapy in patients with moderate-to-severe atopic dermatitis: Combined results from two phase 3, randomized, double-blind, placebo-controlled trials (ECZTRA 1 and 2)
34. 26163 Risankizumab to treat psoriasis in a patient with hepatitis B and hepatitis C
35. 27900 Maintaining long-term improvements in patient-reported symptoms, signs, and quality of life among patients with moderate to severe plaque psoriasis treated with guselkumab: VOYAGE 2, 5-year data
36. Secukinumab demonstrates sustained efficacy in moderate to severe plaque psoriasis across disease severity subgroups: 1731
37. Safety and efficacy of escalating doses of ingenol mebutate in three different vehicle formulations compared to Picato gel 0.05% in the treatment of actinic keratosis on the forearms: 1136
38. First-in-human phase 1 safety study of BLZ-100 in subjects with skin cancer: 1389
39. Preliminary efficacy and safety analysis: 12-month results in 83 patients using a novel approach of widefield radiation therapy for extensive skin field cancerization with or without keratinocyte cancers.
40. Randomized, Placebo-Controlled Phase 1/2 Study to Determine the Appropriate ATX-101 Concentration for Reduction of Submental Fat
41. Management of disseminated superficial actinic porokeratosis and intraepidermal squamous cell carcinoma with low‐dose radiation therapy
42. Atopic Dermatitis Treated Safely with Dupilumab during Pregnancy: A Case Report and Review of the Literature
43. 43887 Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Efficacy by Baseline Demographic and Disease Characteristics in the Phase 3 POETYK PSO-1 and PSO-2 Trials
44. Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials
45. Isotretinoin and mental health in adolescents: Australian consensus
46. Efficacy and safety of lebrikizumab is maintained to two years in patients with moderate-to-severe atopic dermatitis.
47. Method of Assessing Skin Cancerization and KeratosesTM (MASCK™): development and photographic validation in multiple anatomical sites of a novel assessment tool intended for clinical evaluation of patients with extensive skin field cancerization
48. Efficacy And Safety Of Crisaborole In Patients Aged 3 Months To 17 Years With Mild-To-Moderate Atopic Dermatitis
49. Development of Dermatitis Herpetiformis in Chronic Plaque Psoriasis
50. 15904 Efficacy and safety of long-term tildrakizumab for plaque psoriasis: 4-year results from reSURFACE 1
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.